Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
DVA vs FMS vs FXNC vs UNH vs HUM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Banks - Regional
Medical - Healthcare Plans
Medical - Healthcare Plans
DVA vs FMS vs FXNC vs UNH vs HUM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Banks - Regional | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $12.60B | $11.92B | $253M | $335.60B | $29.67B |
| Revenue (TTM) | $13.84B | $19.36B | $112M | $449.71B | $137.20B |
| Net Income (TTM) | $781M | $947M | $18M | $12.04B | $1.13B |
| Gross Margin | 31.1% | 26.0% | 74.0% | 18.8% | 14.0% |
| Operating Margin | 15.0% | 9.7% | 19.6% | 4.2% | 1.0% |
| Forward P/E | 13.8x | 10.5x | 11.7x | 20.2x | 27.7x |
| Total Debt | $15.05B | $10.79B | $43M | $78.39B | $12.94B |
| Cash & Equiv. | $758M | $1.60B | $161M | $24.36B | $4.20B |
DVA vs FMS vs FXNC vs UNH vs HUM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| DaVita Inc. (DVA) | 100 | 242.4 | +142.4% |
| Fresenius Medical C… (FMS) | 100 | 51.3 | -48.7% |
| First National Corp… (FXNC) | 100 | 210.5 | +110.5% |
| UnitedHealth Group … (UNH) | 100 | 121.3 | +21.3% |
| Humana Inc. (HUM) | 100 | 60.2 | -39.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DVA vs FMS vs FXNC vs UNH vs HUM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DVA is the #2 pick in this set and the best alternative if sleep-well-at-night and valuation efficiency is your priority.
- Lower volatility, beta 0.05, current ratio 1.29x
- PEG 1.67 vs FXNC's 7.87
- Beta 0.05 vs FXNC's 0.70
- 4.5% ROA vs FXNC's 0.9%, ROIC 10.5% vs 7.7%
FMS ranks third and is worth considering specifically for income & stability and defensive.
- Dividend streak 4 yrs, beta 0.49, yield 3.8%
- Beta 0.49, yield 3.8%, current ratio 1.26x
- Lower P/E (10.5x vs 27.7x)
- 3.8% yield, 4-year raise streak, vs UNH's 2.4%, (1 stock pays no dividend)
FXNC carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 27.1%, EPS growth 96.0%
- 241.1% 10Y total return vs UNH's 220.6%
- 27.1% NII/revenue growth vs FMS's 1.5%
- 15.8% margin vs HUM's 0.8%
UNH lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, HUM doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.1% NII/revenue growth vs FMS's 1.5% | |
| Value | Lower P/E (10.5x vs 27.7x) | |
| Quality / Margins | 15.8% margin vs HUM's 0.8% | |
| Stability / Safety | Beta 0.05 vs FXNC's 0.70 | |
| Dividends | 3.8% yield, 4-year raise streak, vs UNH's 2.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +46.9% vs FMS's -20.5% | |
| Efficiency (ROA) | 4.5% ROA vs FXNC's 0.9%, ROIC 10.5% vs 7.7% |
DVA vs FMS vs FXNC vs UNH vs HUM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DVA vs FMS vs FXNC vs UNH vs HUM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
FXNC leads in 1 of 6 categories
FMS leads 1 • DVA leads 1 • UNH leads 0 • HUM leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
FXNC leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 4008.0x FXNC's $112M. FXNC is the more profitable business, keeping 15.8% of every revenue dollar as net income compared to HUM's 0.8%. On growth, HUM holds the edge at +23.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $13.8B | $19.4B | $112M | $449.7B | $137.2B |
| EBITDAEarnings before interest/tax | $2.8B | $3.5B | $25M | $23.2B | $2.2B |
| Net IncomeAfter-tax profit | $781M | $947M | $18M | $12.0B | $1.1B |
| Free Cash FlowCash after capex | $1.5B | $1.8B | $21M | $19.7B | $1.3B |
| Gross MarginGross profit ÷ Revenue | +31.1% | +26.0% | +74.0% | +18.8% | +14.0% |
| Operating MarginEBIT ÷ Revenue | +15.0% | +9.7% | +19.6% | +4.2% | +1.0% |
| Net MarginNet income ÷ Revenue | +5.6% | +4.9% | +15.8% | +2.7% | +0.8% |
| FCF MarginFCF ÷ Revenue | +10.8% | +9.1% | +18.7% | +4.4% | +0.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.0% | -5.5% | — | +2.0% | +23.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +43.5% | -15.4% | +7.1% | +0.7% | -4.6% |
Valuation Metrics
FMS leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 11.0x trailing earnings, FMS trades at a 61% valuation discount to UNH's 27.9x P/E. Adjusting for growth (PEG ratio), FMS offers better value at 2.15x vs FXNC's 9.55x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $12.6B | $11.9B | $253M | $335.6B | $29.7B |
| Enterprise ValueMkt cap + debt − cash | $26.9B | $22.7B | $134M | $389.6B | $38.4B |
| Trailing P/EPrice ÷ TTM EPS | 20.64x | 10.96x | 14.27x | 27.95x | 25.12x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.85x | 10.52x | 11.75x | 20.19x | 27.68x |
| PEG RatioP/E ÷ EPS growth rate | 2.49x | 2.15x | 9.55x | — | — |
| EV / EBITDAEnterprise value multiple | 9.87x | 5.91x | 6.13x | 16.70x | 16.87x |
| Price / SalesMarket cap ÷ Revenue | 0.92x | 0.52x | 2.25x | 0.75x | 0.23x |
| Price / BookPrice ÷ Book value/share | 14.93x | 0.75x | 1.35x | 3.31x | 1.68x |
| Price / FCFMarket cap ÷ FCF | 9.61x | 5.98x | 12.03x | 20.88x | 79.13x |
Profitability & Efficiency
Evenly matched — DVA and FXNC each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
DVA delivers a 59.1% return on equity — every $100 of shareholder capital generates $59 in annual profit, vs $6 for HUM. FXNC carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to DVA's 12.99x. On the Piotroski fundamental quality scale (0–9), FMS scores 7/9 vs HUM's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +59.1% | +6.7% | +10.0% | +11.5% | +6.2% |
| ROA (TTM)Return on assets | +4.5% | +3.0% | +0.9% | +3.9% | +2.2% |
| ROICReturn on invested capital | +10.5% | +5.6% | +7.7% | +9.2% | +4.1% |
| ROCEReturn on capital employed | +14.0% | +6.9% | +9.9% | +9.7% | +4.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 7 | 6 | 5 |
| Debt / EquityFinancial leverage | 12.99x | 0.76x | 0.23x | 0.77x | 0.73x |
| Net DebtTotal debt minus cash | $14.3B | $9.2B | -$118M | $54.0B | $8.7B |
| Cash & Equiv.Liquid assets | $758M | $1.6B | $161M | $24.4B | $4.2B |
| Total DebtShort + long-term debt | $15.0B | $10.8B | $43M | $78.4B | $12.9B |
| Interest CoverageEBIT ÷ Interest expense | 3.54x | 10.17x | 0.84x | 4.71x | 3.08x |
Total Returns (Dividends Reinvested)
Evenly matched — DVA and FXNC each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FXNC five years ago would be worth $16,866 today (with dividends reinvested), compared to $5,674 for HUM. Over the past 12 months, FXNC leads with a +46.9% total return vs FMS's -20.5%. The 3-year compound annual growth rate (CAGR) favors DVA at 30.1% vs HUM's -21.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +71.4% | -7.9% | +14.6% | +10.6% | -6.2% |
| 1-Year ReturnPast 12 months | +36.3% | -20.5% | +46.9% | -3.2% | -1.0% |
| 3-Year ReturnCumulative with dividends | +120.0% | +2.2% | +110.8% | -19.9% | -51.9% |
| 5-Year ReturnCumulative with dividends | +54.8% | -35.9% | +68.7% | -2.6% | -43.3% |
| 10-Year ReturnCumulative with dividends | +158.1% | -35.1% | +241.1% | +220.6% | +59.8% |
| CAGR (3Y)Annualised 3-year return | +30.1% | +0.7% | +28.2% | -7.1% | -21.7% |
Risk & Volatility
DVA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DVA is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than FXNC's 0.70 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DVA currently trades 99.6% from its 52-week high vs FMS's 71.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.05x | 0.49x | 0.70x | 0.59x | 0.56x |
| 52-Week HighHighest price in past year | $197.08 | $30.46 | $29.85 | $395.52 | $315.35 |
| 52-Week LowLowest price in past year | $101.00 | $20.02 | $18.31 | $234.60 | $163.11 |
| % of 52W HighCurrent price vs 52-week peak | +99.6% | +71.1% | +93.7% | +93.5% | +78.4% |
| RSI (14)Momentum oscillator 0–100 | 82.2 | 36.5 | 47.6 | 75.9 | 76.6 |
| Avg Volume (50D)Average daily shares traded | 801K | 527K | 80K | 7.9M | 1.6M |
Analyst Outlook
Evenly matched — FMS and UNH each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DVA as "Hold", FMS as "Hold", FXNC as "Buy", UNH as "Buy", HUM as "Hold". Consensus price targets imply 29.4% upside for FMS (target: $28) vs -24.9% for FXNC (target: $21). For income investors, FMS offers the higher dividend yield at 3.78% vs HUM's 1.44%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $168.67 | $28.00 | $21.00 | $385.43 | $246.00 |
| # AnalystsCovering analysts | 23 | 18 | 1 | 52 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | +3.8% | +2.2% | +2.4% | +1.4% |
| Dividend StreakConsecutive years of raises | 3 | 4 | 11 | 25 | 0 |
| Dividend / ShareAnnual DPS | — | $0.70 | $0.61 | $8.70 | $3.56 |
| Buyback YieldShare repurchases ÷ mkt cap | +14.2% | +5.5% | +0.1% | +1.7% | +0.5% |
FXNC leads in 1 of 6 categories (Income & Cash Flow). FMS leads in 1 (Valuation Metrics). 3 tied.
DVA vs FMS vs FXNC vs UNH vs HUM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DVA or FMS or FXNC or UNH or HUM a better buy right now?
For growth investors, First National Corporation (FXNC) is the stronger pick with 27.
1% revenue growth year-over-year, versus 1. 5% for Fresenius Medical Care AG & Co. KGaA (FMS). Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11. 0x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate First National Corporation (FXNC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DVA or FMS or FXNC or UNH or HUM?
On trailing P/E, Fresenius Medical Care AG & Co.
KGaA (FMS) is the cheapest at 11. 0x versus UnitedHealth Group Incorporated at 27. 9x. On forward P/E, Fresenius Medical Care AG & Co. KGaA is actually cheaper at 10. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: DaVita Inc. wins at 1. 67x versus First National Corporation's 7. 87x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — DVA or FMS or FXNC or UNH or HUM?
Over the past 5 years, First National Corporation (FXNC) delivered a total return of +68.
7%, compared to -43. 3% for Humana Inc. (HUM). Over 10 years, the gap is even starker: FXNC returned +241. 1% versus FMS's -35. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DVA or FMS or FXNC or UNH or HUM?
By beta (market sensitivity over 5 years), DaVita Inc.
(DVA) is the lower-risk stock at 0. 05β versus First National Corporation's 0. 70β — meaning FXNC is approximately 1383% more volatile than DVA relative to the S&P 500. On balance sheet safety, First National Corporation (FXNC) carries a lower debt/equity ratio of 23% versus 13% for DaVita Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DVA or FMS or FXNC or UNH or HUM?
By revenue growth (latest reported year), First National Corporation (FXNC) is pulling ahead at 27.
1% versus 1. 5% for Fresenius Medical Care AG & Co. KGaA (FMS). On earnings-per-share growth, the picture is similar: First National Corporation grew EPS 96. 0% year-over-year, compared to -14. 7% for UnitedHealth Group Incorporated. Over a 3-year CAGR, HUM leads at 11. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DVA or FMS or FXNC or UNH or HUM?
First National Corporation (FXNC) is the more profitable company, earning 15.
8% net margin versus 0. 9% for Humana Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FXNC leads at 19. 6% versus 1. 1% for HUM. At the gross margin level — before operating expenses — FXNC leads at 74. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DVA or FMS or FXNC or UNH or HUM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, DaVita Inc. (DVA) is the more undervalued stock at a PEG of 1. 67x versus First National Corporation's 7. 87x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Fresenius Medical Care AG & Co. KGaA (FMS) trades at 10. 5x forward P/E versus 27. 7x for Humana Inc. — 17. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FMS: 29. 4% to $28. 00.
08Which pays a better dividend — DVA or FMS or FXNC or UNH or HUM?
In this comparison, FMS (3.
8% yield), UNH (2. 4% yield), FXNC (2. 2% yield), HUM (1. 4% yield) pay a dividend. DVA does not pay a meaningful dividend and should not be held primarily for income.
09Is DVA or FMS or FXNC or UNH or HUM better for a retirement portfolio?
For long-horizon retirement investors, UnitedHealth Group Incorporated (UNH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
59), 2. 4% yield, +220. 6% 10Y return). Both have compounded well over 10 years (UNH: +220. 6%, FXNC: +241. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DVA and FMS and FXNC and UNH and HUM?
These companies operate in different sectors (DVA (Healthcare) and FMS (Healthcare) and FXNC (Financial Services) and UNH (Healthcare) and HUM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DVA is a mid-cap quality compounder stock; FMS is a mid-cap deep-value stock; FXNC is a small-cap high-growth stock; UNH is a large-cap quality compounder stock; HUM is a mid-cap quality compounder stock. FMS, FXNC, UNH, HUM pay a dividend while DVA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.